Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAEL-101 plus plasma cell dyscrasia treatment versus placebo plus plasma cell dyscrasia treatment in treatment-naive Mayo stage IIIa AL amyloidosis
2022-503072-84-00Phase 3Authorised
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in light-chain amyloidosis comparing Anselamimab plus plasma cell dyscrasia treatment with Placebo plus plasma cell dyscrasia treatment (2 arms). Primary endpoints: Hierarchical combination of all-cause mortality and cardiovascular hospitalizations and Safety and tolerability. Planned start Jun 2024; status: authorised.
02
Drugs
anselamimab
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2022-503072-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503072-84-00.